AR018652A1 - Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores - Google Patents

Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores

Info

Publication number: AR018652A1
Authority: AR; Argentina
Prior art keywords: alkyl; group; carbon; het; substituted
Prior art date: 1998-06-12

Application number

ARP990102767A

Other languages

English (en)

Spanish (es)

Original Assignee

Smithkline Beecham Corp

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

1999-06-10

Publication date

2001-11-28

1999-06-10 Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp

2001-11-28 Publication of AR018652A1 publication Critical patent/AR018652A1/es

Links

239000003112 inhibitor Substances 0.000 title 2
150000001875 compounds Chemical class 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 16
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 4
125000001624 naphthyl group Chemical group 0.000 abstract 3
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
150000002431 hydrogen Chemical group 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
229940122156 Cathepsin K inhibitor Drugs 0.000 abstract 1
PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 abstract 1
LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000001931 aliphatic group Chemical group 0.000 abstract 1
125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 abstract 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 abstract 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Chemical group 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Cosmetics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)

ARP990102767A 1998-06-12 1999-06-10 Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores AR018652A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8905698P	1998-06-12	1998-06-12

Publications (1)

Publication Number	Publication Date
AR018652A1 true AR018652A1 (es)	2001-11-28

Family

ID=22215426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP990102767A AR018652A1 (es)	1998-06-12	1999-06-10	Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores

Country Status (10)

Country	Link
EP (1)	EP1086083A4 (fr)
JP (1)	JP2002517485A (fr)
AR (1)	AR018652A1 (fr)
AU (1)	AU4564499A (fr)
CA (1)	CA2334652A1 (fr)
CO (1)	CO5040090A1 (fr)
DZ (1)	DZ2815A1 (fr)
MA (1)	MA24877A1 (fr)
PE (1)	PE20000725A1 (fr)
WO (1)	WO1999064399A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030144175A1 (en)	1998-12-23	2003-07-31	Smithkline Beecham Corporation	Protease inhibitors
WO2001034600A1 (fr)	1999-11-10	2001-05-17	Smithkline Beecham Corporation	Inhibiteurs de protease
JP2003513924A (ja)	1999-11-10	2003-04-15	スミスクライン・ビーチャム・コーポレイション	プロテア−ゼ阻害剤
AU1588901A (en)	1999-11-10	2001-06-06	Smithkline Beecham Corporation	Protease inhibitors
OA12323A (en)	2000-03-21	2006-05-15	Smithkline Beecham Corp	Protease inhibitors.
WO2002080920A1 (fr) *	2001-04-06	2002-10-17	Axys Pharmaceuticals, Inc.	Arylacetamido-cetobenzoxazole comme inhibiteurs de la cysteine protease
US7282512B2 (en)	2002-01-17	2007-10-16	Smithkline Beecham Corporation	Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
JP5587790B2 (ja)	2008-01-09	2014-09-10	アミュラセラピューティクスリミティド	化合物
WO2023041432A1 (fr)	2021-09-14	2023-03-23	Boehringer Ingelheim International Gmbh	Dérivés de 3-phénoxyazétidin-1-yl-hétéroaryl-pyrrolidine et leur utilisation en tant que médicament

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9408019A (pt) *	1993-11-09	1997-08-26	Merck & Co Inc	Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
US5770573A (en) *	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5618792A (en) *	1994-11-21	1997-04-08	Cortech, Inc.	Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase

1999
- 1999-06-09 DZ DZ990115A patent/DZ2815A1/fr active
- 1999-06-10 AR ARP990102767A patent/AR018652A1/es unknown
- 1999-06-10 MA MA25619A patent/MA24877A1/fr unknown
- 1999-06-10 CO CO99036559A patent/CO5040090A1/es unknown
- 1999-06-11 EP EP99928614A patent/EP1086083A4/fr not_active Withdrawn
- 1999-06-11 AU AU45644/99A patent/AU4564499A/en not_active Abandoned
- 1999-06-11 PE PE1999000518A patent/PE20000725A1/es not_active Application Discontinuation
- 1999-06-11 CA CA002334652A patent/CA2334652A1/fr not_active Abandoned
- 1999-06-11 JP JP2000553408A patent/JP2002517485A/ja not_active Withdrawn
- 1999-06-11 WO PCT/US1999/013334 patent/WO1999064399A1/fr not_active Ceased

Also Published As

Publication number	Publication date
MA24877A1 (fr)	1999-12-31
WO1999064399A1 (fr)	1999-12-16
PE20000725A1 (es)	2000-09-28
CA2334652A1 (fr)	1999-12-16
JP2002517485A (ja)	2002-06-18
EP1086083A4 (fr)	2001-09-26
DZ2815A1 (fr)	2003-12-01
EP1086083A1 (fr)	2001-03-28
CO5040090A1 (es)	2001-05-29
AU4564499A (en)	1999-12-30

Publication	Publication Date	Title
AR041271A1 (es)	2005-05-11	Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
AR064731A1 (es)	2009-04-22	Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR064732A1 (es)	2009-04-22	Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
CO5021213A1 (es)	2001-03-27	INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
AR048641A1 (es)	2006-05-10	Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR016523A1 (es)	2001-07-25	Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
ES2139943T3 (es)	2000-02-16	Nuevos inhibidores de la sintasa de prostaglandina.
CO6241076A2 (es)	2011-01-20	Compuestos de benzamida y aplicaciones de los mismos
AR018186A1 (es)	2001-10-31	Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
AR008377A1 (es)	2000-01-19	Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR016307A1 (es)	2001-07-04	Imidazopirimidinas e imidazopiridinas, metodo para el tratamiento de afecciones neurologicas, y composicion farmaceutica.
UY25204A1 (es)	2000-12-29	Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
AR020562A1 (es)	2002-05-15	Inhibidores de la sorbitol deshidrogenasa
ECSP034865A (es)	2004-01-28	Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
ECSP066968A (es)	2006-12-29	Compuestos de metil-aril o heteroaril-amida sustituida
AR072510A1 (es)	2010-09-01	Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana
WO2001057021A3 (fr)	2002-02-14	2-[1H]-QUINOLONE ET 2-[1H]-QUINOXALONE INHIBITEURS DU FACTEUR Xa
AR055041A1 (es)	2007-08-01	Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
ATE546467T1 (de)	2012-03-15	Ortho-nitrosophenole als polymerisationshemmer
AR013608A1 (es)	2001-01-10	Derivados de 3,4-diariloxazolona, procedimiento para su preparacion, y composicion farmaceutica que los comprende.
CO5700747A2 (es)	2006-11-30	Piperidinas novedosas como moduladores de quimoquina (ccr)
AR033683A1 (es)	2004-01-07	Compuestos de ciclobutendiona , procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR027559A1 (es)	2003-04-02	Metodo para la preparacion de citalopram
CO5040090A1 (es)	2001-05-29	Inhibidores de proteasas
AR018675A1 (es)	2001-11-28	Derivados de 3-(2-oxo-[1,3¿i¿]bipirrolidinil-3-ilidenometil)-cefem, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento.